Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | SENIOR VICE PRESIDENT | February 28, 2023 | March 03, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date February 28, 2023 · Filed March 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 38,092 |
Ending reported balance
After 2023-02-28 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-02-28 · Grant · Acquired 12,322 · Balance 38,784 F1: Settlement of performance-based restricted stock units in shares in a transaction exempt from Section 16(b) under Rule 16b-3. Row 2 · 2023-02-28 · Tax withholding · Disposed 692 · Balance 38,092 |
Filing footnotes · ownership attribution and instrument terms
F1: Settlement of performance-based restricted stock units in shares in a transaction exempt from Section 16(b) under Rule 16b-3.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2023 Filed Mar 3, 2023 00:38 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 692 | $99.77 | $69,040.84 |
DisclosureSEC source: 0001415889-23-003909 · form4-03032023_120321.xml · nonDerivative · entry 2 Karam Sammy · CIK 0001766718 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,092 Read SEC document |
| February 28, 2023 Filed Mar 3, 2023 00:38 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 12,322 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-003909 · form4-03032023_120321.xml · nonDerivative · entry 1 Karam Sammy · CIK 0001766718 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,784 F1 · shares: Settlement of performance-based restricted stock units in shares in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 23:58 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 45,812 | $0.00 Strike: $106.24 | $0.00 |
DisclosureSEC source: 0001415889-23-003054 · form4-02222023_110235.xml · derivative · entry 1 Karam Sammy · CIK 0001766718 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,812 Underlying: Common Shares · 45,812 shares Expires 2033-02-16 F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 15,270 on February 17, 2024, 15,271 on February 17, 2025, and 15,271 on February 17, 2026. Read SEC document |
| December 29, 2022 Filed Jan 3, 2023 22:32 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 4,200 | $108.75 | $456,750.00 |
DisclosureSEC source: 0001415889-23-000127 · form4-01032023_100142.xml · nonDerivative · entry 1 Karam Sammy · CIK 0001766718 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,462 Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 00:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 802 | $122.41 | $98,172.82 |
DisclosureSEC source: 0001415889-22-002194 · form4-03022022_040352.xml · nonDerivative · entry 2 Karam Sammy · CIK 0001766718 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,662 Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 00:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 13,238 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-002194 · form4-03022022_040352.xml · nonDerivative · entry 1 Karam Sammy · CIK 0001766718 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,464 F1 · shares: Settlement of performance-based restricted stock units in shares in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 18, 2022 Filed Feb 24, 2022 01:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 59,708 | $0.00 Strike: $117.58 | $0.00 |
DisclosureSEC source: 0001415889-22-001739 · form4-02232022_050241.xml · derivative · entry 1 Karam Sammy · CIK 0001766718 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,708 Underlying: Common Shares · 59,708 shares Expires 2032-02-17 F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 19,902 on February 18, 2023, 19,903 on February 18, 2024, and 19,903 on February 18, 2025. Read SEC document |
| December 23, 2021 Filed Dec 28, 2021 22:39 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 4,700 | $140.00 | $658,023.03 |
DisclosureSEC source: 0001415889-21-006264 · form4-12282021_021229.xml · nonDerivative · entry 1 Karam Sammy · CIK 0001766718 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,226 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $140 to $140.01, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 22:29 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 8,000 | $0.00 Strike: $75.90 | $0.00 |
DisclosureSEC source: 0001415889-21-004019 · form4-08192021_030830.xml · derivative · entry 3 Karam Sammy · CIK 0001766718 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,978 Underlying: Common Shares · 8,000 shares Expires 2029-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 22:29 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 8,000 | $125.00 | $1,000,000.00 |
DisclosureSEC source: 0001415889-21-004019 · form4-08192021_030830.xml · nonDerivative · entry 2 Karam Sammy · CIK 0001766718 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,926 Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 22:29 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 8,000 | $75.90 | $607,200.00 |
DisclosureSEC source: 0001415889-21-004019 · form4-08192021_030830.xml · nonDerivative · entry 1 Karam Sammy · CIK 0001766718 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:40 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 8,000 | $0.00 Strike: $75.90 | $0.00 |
DisclosureSEC source: 0001415889-21-003804 · form4-08052021_020853.xml · derivative · entry 3 Karam Sammy · CIK 0001766718 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,978 Underlying: Common Shares · 8,000 shares Expires 2029-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:40 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 8,000 | $122.50 | $980,000.00 |
DisclosureSEC source: 0001415889-21-003804 · form4-08052021_020853.xml · nonDerivative · entry 2 Karam Sammy · CIK 0001766718 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,926 Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:40 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 8,000 | $75.90 | $607,200.00 |
DisclosureSEC source: 0001415889-21-003804 · form4-08052021_020853.xml · nonDerivative · entry 1 Karam Sammy · CIK 0001766718 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 22:42 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 8,600 | $0.00 Strike: $75.90 | $0.00 |
DisclosureSEC source: 0001415889-21-002195 · form4-04292021_030442.xml · derivative · entry 3 Karam Sammy · CIK 0001766718 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,978 Underlying: Common Shares · 8,600 shares Expires 2029-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 22:42 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 8,600 | $122.00 | $1,049,200.00 |
DisclosureSEC source: 0001415889-21-002195 · form4-04292021_030442.xml · nonDerivative · entry 2 Karam Sammy · CIK 0001766718 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,926 Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 22:42 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 8,600 | $75.90 | $652,740.00 |
DisclosureSEC source: 0001415889-21-002195 · form4-04292021_030442.xml · nonDerivative · entry 1 Karam Sammy · CIK 0001766718 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,526 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2021 Filed Mar 3, 2021 00:36 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 3,910 | $121.58 | $475,377.80 |
DisclosureSEC source: 0001415889-21-001208 · form4-03022021_040317.xml · nonDerivative · entry 2 Karam Sammy · CIK 0001766718 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,926 Read SEC document |
| February 26, 2021 Filed Mar 3, 2021 00:36 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 9,772 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-001208 · form4-03022021_040317.xml · nonDerivative · entry 1 Karam Sammy · CIK 0001766718 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,836 F1 · shares: Settlement of performance-based restricted stock units in shares in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 23:56 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 53,326 | $0.00 Strike: $124.04 | $0.00 |
DisclosureSEC source: 0001415889-21-000894 · form4-02232021_030246.xml · derivative · entry 1 Karam Sammy · CIK 0001766718 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,326 Underlying: Common Shares · 53,326 shares Expires 2031-02-18 F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 17,775 on February 19, 2022, 17,775 on February 19, 2023, and 17,776 on February 19, 2024. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 22:43 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 857 | $128.23 | $109,893.11 |
DisclosureSEC source: 0001415889-21-000749 · form4-02182021_020257.xml · nonDerivative · entry 1 Karam Sammy · CIK 0001766718 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,064 Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 22:31 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,972 | $79.19 | $156,162.68 |
DisclosureSEC source: 0001179110-20-002925 · edgar.xml · nonDerivative · entry 2 Karam Sammy · CIK 0001766718 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,921 Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 22:31 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 5,188 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002925 · edgar.xml · nonDerivative · entry 1 Karam Sammy · CIK 0001766718 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,893 F1 · shares: Settlement of performance-based restricted stock units in shares in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:30 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 83,818 | $0.00 Strike: $87.72 | $0.00 |
DisclosureSEC source: 0001179110-20-002284 · edgar.xml · derivative · entry 1 Karam Sammy · CIK 0001766718 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,818 Underlying: Common shares · 83,818 shares Expires 2030-02-20 F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 27,939 on February 21, 2021, 27,939 on February 21, 2022, and 27,940 on February 21, 2023. Read SEC document |
| February 17, 2020 Filed Feb 19, 2020 22:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 771 | $89.66 | $69,127.86 |
DisclosureSEC source: 0001179110-20-001884 · edgar.xml · nonDerivative · entry 2 Karam Sammy · CIK 0001766718 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,705 Read SEC document |
| February 16, 2020 Filed Feb 19, 2020 22:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 814 | $89.66 | $72,983.24 |
DisclosureSEC source: 0001179110-20-001884 · edgar.xml · nonDerivative · entry 1 Karam Sammy · CIK 0001766718 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,476 Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 81,578 | $0.00 Strike: $75.90 | $0.00 |
DisclosureSEC source: 0001179110-19-002643 · edgar.xml · derivative · entry 1 Karam Sammy · CIK 0001766718 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,578 Underlying: Common shares · 81,578 shares Expires 2029-02-21 F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 27,192 on February 22, 2020, 27,193 on February 22, 2021, and 27,193 on February 22, 2022. Read SEC document |
| February 19, 2019 Filed Feb 20, 2019 22:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 792 | $75.25 | $59,598.00 |
DisclosureSEC source: 0001179110-19-002152 · edgar.xml · nonDerivative · entry 3 Karam Sammy · CIK 0001766718 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,290 Read SEC document |
| February 17, 2019 Filed Feb 20, 2019 22:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 771 | $75.25 | $58,017.75 |
DisclosureSEC source: 0001179110-19-002152 · edgar.xml · nonDerivative · entry 2 Karam Sammy · CIK 0001766718 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,082 Read SEC document |
| February 16, 2019 Filed Feb 20, 2019 22:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 814 | $75.25 | $61,253.50 |
DisclosureSEC source: 0001179110-19-002152 · edgar.xml · nonDerivative · entry 1 Karam Sammy · CIK 0001766718 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,853 F1 · balance_after: Includes shares acquired under the Abbott Laboratories 2017 Employee Stock Purchase Plan for Non-U.S. Employees. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.